Cravath, Swaine & Moore LLP Logo
  • Practices
  • People
  • Careers
  • News & Insights
  • Practices
  • People
  • Careers
  • News & Insights
  • Our Story
  • The Cravath System
  • Diversity & Inclusion
  • Pro Bono
  • Alumni Journal
  • 200.Cravath

Cravath’s London Office Moves to 100 Cheapside

Read More

News & Insights

Richard Hall Speaks at Tulane University Law School’s 37th Corporate Law Institute

March 07, 2025

On March 7, 2025, Cravath partner Richard Hall spoke at the 37th Corporate Law Institute, which was hosted by Tulane University Law School from March 6‑7, 2025, in New Orleans, Louisiana, and featured members of the judiciary, journalists and leading corporate counsel and investment bankers to discuss the latest developments in M&A, corporate and securities law. Richard spoke on a panel entitled “Regulatory Merger Control Regimes – M&A in a Time of Regulatory Uncertainty.”

Related Practices & Industries

  • Corporate
  • Mergers and Acquisitions
  • Antitrust

Speakers

Photo
Name
Richard Hall
Title
Corporate
Title
Partner
Email
rhall@cravath.com
Phone
+1-212-474-1293
vCard
Download vCard

    Education

    • LL.M., 1988, Harvard Law School
    • LL.B., 1986, University of Melbourne
      with Honors
    • B.Com., 1984, University of Melbourne
      with Honors

    Admitted In

    • New York

    Related News & Insights

    Deals & Cases

    April 30, 2024

    Sensata Technologies’ Cooperation Agreement with Elliott

    On April 29, 2024, Sensata Technologies Holding plc (“Sensata Technologies”), a global industrial technology company, announced that it has entered into a Cooperation Agreement with Elliott Investment Management L.P. (“Elliott”). The Cooperation Agreement contains customary standstill, voting and other provisions. Cravath is representing Sensata Technologies in connection with the agreement.

    Deals & Cases

    February 12, 2024

    CymaBay Therapeutics’ $4.3 Billion Acquisition by Gilead Sciences

    On February 12, 2024, CymaBay Therapeutics (“CymaBay”) and Gilead Sciences, Inc. (“Gilead”) announced a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion. The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis, complements Gilead’s existing liver portfolio and aligns with its longstanding commitment to bringing transformational medicines to patients. Cravath is representing CymaBay in connection with the transaction.

    Deals & Cases

    November 21, 2023

    Amentum’s Merger with Jacobs’ Critical Mission Solutions and Cyber and Intelligence Businesses

    On November 20, 2023, Amentum, a portfolio company of Lindsay Goldberg and American Securities, announced a definitive agreement to merge with Jacobs’ Critical Mission Solutions and Cyber and Intelligence businesses, creating a new leader in systems integration and technology solutions. The transaction, which is structured as an all‑stock, Reverse Morris Trust transaction, will result in a publicly traded combined organization with $13 billion in revenue and more than 53,000 employees in 83 countries. Cravath is representing Amentum in connection with the transaction.

    Deals & Cases

    September 12, 2023

    WestRock’s $20 Billion Combination with Smurfit Kappa to Create Global Leader in Sustainable Packaging

    On September 12, 2023, the Boards of WestRock and Smurfit Kappa announced the signing of a definitive transaction agreement to create Smurfit WestRock, a global leader in sustainable packaging. Together, Smurfit Kappa and WestRock generated combined last twelve months’ adjusted annual revenue of approximately $34 billion as of June 30, 2023. Cravath is representing WestRock in connection with the transaction.

    Cravath Bicentennial

    Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.

    Explore

    Cravath, Swaine & Moore LLP Logo
    • CONTACT US
    • OUR STORY
    • ALUMNI PORTAL
    • DISCLAIMERS & NOTICES

    Attorney Advertising. ©2025 Cravath, Swaine & Moore LLP.